D the relative reduction in HCV RNA level from before treatment to day 2 after logarithmic transformation.
Results. A log 10 HCV RNA value р0.8 showed a 95% negative predictive value for virological response, (t Ϫt ) 0 2 D whereas one 12.5 had a 93% positive predictive value for virological response, independent of genotype and histology. The log 10 HCV RNA value was strictly related to final treatment outcome and could differentiate D not only patients with a sustained virological response from nonresponders but also patients who experienced relapse from the former. The log 10 HCV RNA value was highest among patients infected with genotypes 2 (t Ϫt ) 0 2 D and 3 and was lowest among patients infected with genotype 1. It decreased with increasing grades of fibrosis and steatosis and was also inversely related to g-glutamyl transpeptidase (GGT) level and HOMA-IR (homeostasis model assessment for insulin resistance) score. In multivariate analysis, log 10 HCV RNA value was the (t Ϫt ) 0 2 D strongest predictor of sustained virological response and appeared to be independently related to viral genotype and GGT level.
Conclusion. HCV RNA kinetics has strong predictive value. It correlates with virological and clinical parameters that are known predictors of antiviral treatment outcome, including insulin resistance. The measurement of HCV load as early as 2 days after the start of pegylated interferon and ribavirin is a useful tool for the prediction of treatment outcome in individual patients and should be used in clinical practice.
Serial measurements of serum hepatitis C virus (HCV) load during antiviral treatment may provide insights into the intrinsic susceptibility of the viral quasispecies to interferon alfa [1, 2] . Mathematical modeling of these measurements has revealed the existence of a biphasic pattern of viral load decline in patients showing susceptibility to interferon alfa [3] . When it occurs, the first phase of the drop in HCV load encompasses the ings obtained in patients treated with unconjugated interferon alfa and showed that evaluation of the early kinetics of HCV allows one to tailor the duration of treatment and to predict its outcome [11] [12] [13] . However, these studies were partially limited by having been performed in relatively small and/or selected subsets of patients with chronic hepatitis C. Moreover, host factors such as steatosis, visceral obesity, and insulin resistance-which are currently regarded as major determinants of antiviral treatment outcome in chronic hepatitis C [14-17]-were not evaluated.
In the present study, we investigated a large, well-characterized cohort of patients with chronic hepatitis C to assess the clinical, virological, and biochemical correlates of first-phase HCV RNA kinetics and analyze its possible prognostic value for the outcome of treatment.
METHODS

Study design.
This was a prospective study of the determinants of the outcome of combination antiviral treatment for chronic hepatitis C, started in our unit in 2002. The study protocol was approved by the Second University of Naples Ethics Committee, and all procedures were performed in accordance with the 1976 Declaration of Helsinki. The primary study end point was the sustained virological response to antiviral treatment.
Patients included and treatment administered. We enrolled in this study 119 previously untreated patients with chronic hepatitis C, who provided informed consent. Inclusion criteria were age 118 years, repeated evidence of elevated alanine aminotransferase (ALT) levels within 12 months before study entry, presence of a measurable serum HCV RNA load, evidence of chronic active hepatitis on liver biopsy, and willingness to cope (at best) with adverse effects and complete the prescribed treatment course. Excluded were patients who showed evidence of alcohol, illicit drug, or potentially hepatotoxic medication use; of coinfection with hepatitis B virus, hepatitis D virus, or human immunodeficiency virus; or of the presence of other liver disorders. All patients were white and came from our geographic area. During the accrual time, 55 patients did not meet the study criteria.
The treatment regimen consisted of either pegylated interferon alfa-2a (180 mg subcutaneously once a week) or pegylated interferon alfa-2b (1.5 mg per kilogram of body weight subcutaneously once a week), as chosen by the physician in charge. All subjects received combination treatment with ribavirin, at 800 mg/day (400 mg twice a day) for those infected with HCV genotype 2 or 3 and at 1000 or 1200 mg/day for subjects infected with genotype 1 weighing !75 or у75 kg, respectively. The predetermined length of treatment was 48 weeks for patients infected with genotype 1 and 24 weeks for patients infected with genotypes other than 1, with a final efficacy evaluation at week 24 of follow-up. Treatment was discontinued at week 12 in patients showing a р2 log 10 decline in HCV RNA level from baseline. The first 5 doses of pegylated interferon were administered personally in the outpatient clinic office by one of us.
Treatment outcome was assessed as follows: rapid virological response (RVR) and early virological response (EVR) were defined as undetectable HCV RNA at treatment week 4 or 12, respectively; sustained virological response (SVR) was defined as undetectable HCV RNA 24 weeks after treatment discontinuation; relapse was defined as HCV RNA clearance during treatment and reappearance during follow-up; and nonresponse was defined as a failure to clear HCV RNA at any time during treatment [18] . Medication doses were reduced in accordance with current practice recommendations [19] . For the purpose of the evaluation of clinical outcome, an intent-totreat (ITT) analysis was used (ie, patients discontinuing treatment for adverse events or dropping out before completing at least 12 weeks of treatment were considered to be nonresponsive irrespective of the extent of viral load decline experienced).
Clinical and virological evaluation. The following parameters were obtained and recorded during patient screening: age, sex, height, weight, body mass index, waist circumference, viral genotype (INNO-LiPA; Innogenetics), and serum HCV RNA level (Amplicor HCV Monitor 2.0; Roche). Overweight, obesity, visceral obesity, and insulin resistance were defined according to the current standard criteria [20] . All patients underwent percutaneous liver biopsy before the start of treatment. Liver histology was evaluated by standard techniques, as described elsewhere [21, 22] .
Among the laboratory parameters measured at baseline, serum levels of glucose, aminotransferases (ALT and aspartate aminotransferase), g-glutamyl transpeptidase (GGT), insulin, and ferritin were recorded and included in the analysis. The degree of insulin resistance was measured according to the homeostasis model assessment for insulin resistance:
, where FPGL is the fasting HOMA-IR p (FPGL ϫ FIL) /22.5 plasma glucose level measured in micromoles per liter and FIL is the fasting insulin level measured in microunits per milliliter. Assays were performed by our hospital laboratory on serum samples obtained from subjects after overnight fasting. Insulin levels were measured by radioimmunoassay (Diagnostic Systems Laboratories).
Blood samples for the kinetics study were obtained after overnight fasting from all patients 5 min before and 2, 14, and 28 days after the administration of the first dose of pegylated interferon and the first ribavirin tablets. Additional samples were obtained on days 90 and 180 of treatment, at the end of treatment, and 6 months later (end of follow-up). Samples were NOTE. Data are means ‫ע‬ standard deviations, unless otherwise indicated. ALT, alanine transaminase; BMI, body mass index (calculated as the weight in kilograms divided by the square of height in meters); HCV, hepatitis C virus; GGT, g-glutamyl transpeptidase; HOMA-IR, homeostasis model assessment for insulin resistance; NA, not applicable; SVR, sustained virological response; ULN, upper limit of normal.
a For the comparison of genotype 1 versus genotype 2 or 3.
centrifuged at room temperature 30 min after being obtained, and serum samples were cryopreserved at Ϫ80ЊC until further use. For these specimens, HCV RNA levels were measured by branched DNA assay (Versant HCV RNA 3.0; Bayer Diagnostics). The assay has a lower limit of detection of 615 IU/mL. Day 2 samples that tested negative for HCV RNA by the branched DNA assay were reassayed by qualitative polymerase chain reaction (PCR) (Amplicor HCV Monitor 2.0; Roche); this assay has a sensitivity of 50 IU/mL. End-of-treatment and end-of-follow-up samples were assayed by the same qualitative PCR.
To assess first-phase HCV RNA kinetics, we evaluated the relative reduction in HCV RNA level from baseline after logarithmic transformation, calculating for each patient the log 10 HCV RNA value, where D is the difference between (t Ϫt ) 0 2 D 2 HCV RNA determinations, t 0 is the baseline (day 0) determination, and t 2 is the determination made on day 2 after the start of treatment. Statistical evaluation. Analyses were done using SPSS software, version 11.5 (SPSS). The significance level was set at 5%, and all tests were 2-tailed.
The distribution of numerical variables was evaluated by skewness and was found to be mostly nonnormal; thus, nonparametric tests were used. When a posteriori between-group studies were needed, analysis of variance with the Bonferroni post-hoc test was performed.
Differences in numerical variables between groups were assessed by the Mann-Whitney U or the Kruskal-Wallis test for 2 or multiple independent samples, respectively. The possible relationship between 2 numerical variables was assessed by Spearman simple rank correlation.
To evaluate the performance of a treatment outcome clas- for the comparison of patients who experienced relapse and those who P p .397 experienced nonresponse). After 2 days of treatment, patients who subsequently developed a SVR had a significantly greater log decline in HCV RNA level than did either those who experienced relapse or those who experienced nonresponse-median log 10 HCV RNA values were 2.27 for
D patients with a SVR versus 1.39 and 1.02 for patients who experienced relapse and nonresponse, respectively ( ). C, Linear HCV RNA decline P ! .001 from day 0 to 2 in the 3 study groups, further graphically depicting the difference between patients experiencing a SVR, relapse, and nonresponse in terms of initial HCV RNA decline. Each line represents 1 patient. Thick black lines in each graph represent the median slopes, which clearly differentiate the 3 groups with different treatment outcomes. NR, nonresponse; RLPS, relapse. Variables that were associated with treatment outcome or extent of viral load decline in univariate analysis ( ) or P ! .1 that were judged to be clinically relevant were block-entered into multiple logistic and linear regression models, respectively. The dependent variables were treatment outcome (SVR vs relapse or nonresponse) in the logistic regression analysis and log 10 HCV RNA value (ie, the day 2 decline in HCV (t Ϫt ) 0 2 D RNA level) in the linear regression analysis. Factor analysis was applied whenever feasible, to rule out collinearity among covariates before entering them into the models. The goodness of fit of the logistic regression model was assessed by the Hosmer-Lemeshow test. Numerical data are presented as means ‫ע‬ standard deviations or as medians and interquartile ranges. Categorical data are presented as numbers and percentages. 
RESULTS
Clinical features of patients and treatment outcome.
Included in the study were 119 subjects, whose clinical characteristics are presented in In this study, we first analyzed patient data to evaluate the relationship between early changes in HCV RNA level and final treatment outcome. Subsequently, we assessed the potential of early HCV RNA kinetics in terms of predicting the final treatment outcome. Finally, we evaluated the relationship between the extent of early HCV RNA changes and various clinical and virological parameters that are known predictors of treatment outcome.
First-phase HCV RNA decline and treatment outcome. We examined the extent of the HCV RNA decline in terms of changes in logarithmic viremia levels from baseline to day 2-the log 10 HCV RNA value-in patients grouped accord-
D ing to treatment outcome. As depicted in figure 1 , the first phase of the HCV RNA decline (0-2 days of treatment) clearly differentiated patients who had SVRs from those who did not, independent of all other parameters. Also, it differentiated patients with SVRs from those who experienced relapse but not the latter from patients who experienced nonresponse.
Predictive value of the first-phase HCV RNA kinetics. In view of the clear-cut differences observed as early as 2 days after the start of treatment, we attempted to assess the predictive value of the log 10 HCV RNA parameter for final treat- D log 10 HCV RNA value 12.5 had a positive predictive value of 88% and a negative predictive value of 54%. Thus, using a rigorous ITT analysis we found that a decline in HCV RNA level р0.8 logs as early as 2 days after the start of treatment predicted an unfavorable outcome (relapse or nonresponse) with 95% accuracy. Conversely, a 2-day drop of 12.5 logs implied an 88% probability of the development of a SVR (table  2) . These predictive values were independent of any other parameter (such as viral genotype, liver fibrosis stage, and patient age or sex) and were based on an ITT analysis of the primary study end point. We also performed a per-protocol outcome analysis excluding the 5 patients who withdrew prematurely because of adverse events. In this analysis, the negative predictive value of an HCV RNA decline р0.8 logs was 95%, and the positive predictive value of a decline 12.5 logs was 93%.
Correlates of first-phase HCV RNA kinetics. We subsequently analyzed the correlation between the first-phase HCV kinetics and various clinical and virological parameters. The log 10 HCV RNA value correlated with RVR ( ), (t Ϫt ) 0 2 D P ! .001 whereas it showed no relationship with patient age or sex or with the subtype of pegylated interferon alfa administered (data not shown).
Among histological parameters (figure 2), liver fibrosis stage was significantly related to the first-phase decline. In figure 2A , it can be seen that subjects with mild or moderate fibrosis (F1 or F2) had significantly greater log 10 ). Moreover, the extent of the HCV RNA P p .001 decline was found to progressively decrease with increasing fibrosis stage (figure 2B).
The degree of early HCV RNA decline was also related to the extent of liver steatosis. As shown in figure 2C , an almost linear indirect relationship was observed between steatosis grade and the log 10 HCV RNA parameter. Interestingly, (t Ϫt ) 0 2 D this relationship did not exist among subjects with the highest degrees of steatosis. This paradoxical finding was due to the prevalence of genotype 3-infected subjects (100%) within the subgroup of 6 patients with grade 3 steatosis (ie, involving 166% of hepatocytes). Coherently, the inverse relationship between steatosis and log 10 HCV RNA value was strongest (t Ϫt ) 0 2 D when we restricted the analysis to genotype 1-infected patients (data not shown).
Viral genotype was in fact confirmed to be a major virological determinant of the extent of the HCV RNA decline over the first 2 days of treatment. Figure 3 shows the relationship between viral factors and the first-phase HCV RNA kinetics. Patients infected with HCV genotype 1 had significantly lower log 10 HCV RNA values than did those infected with figure 3B) .
To complete the univariate analysis of factors associated with early HCV RNA decline, we looked at its possible correlation with the remaining clinical and analytical parameters recorded. Interestingly, we found that both serum ALT and GGT levels were inversely related to the extent of the early HCV RNA decline (for GGT, and ; for ALT, and r p Ϫ0.475 P ! .001 r p Ϫ0.312 ) ( figure 4A and 4B) . In particular, a strict indirect P p .001 relationship was observed between serum GGT levels and log 10 HCV RNA value. Because GGT levels correlated (table 3) .
By means of a multivariate linear regression model that included fibrosis, steatosis, HCV genotype, ALT and GGT levels, and insulinemia, we found that the independent predictors of the first-phase viral response to treatment were HCV genotype and GGT level (table 3) .
DISCUSSION
The currently available treatment for chronic hepatitis C has an overall suboptimal efficacy in the face of significant toxicity [19] . During-treatment predictors of outcome have succeeded in avoiding the useless financial and human burdens of ineffective treatments in refractory subjects [23, 24] . It is presently recommended that medications be withdrawn whenever a RVR or an EVR is not achieved [19] . The results of the present study show that it is possible to predict treatment outcome with reasonable confidence in a substantial number of cases as early as 2 days after the start of treatment. Indeed, our clinical experience suggests that evaluation of first-phase HCV RNA kinetics may in many cases function as an in vivo antiviral susceptibility test.
Three major findings arise from our study. First, evaluation of the HCV RNA decline after the first 2 days of combination antiviral treatment clearly discriminates among patient groups with different outcomes. Second, the application of 2 different cutoff values for day 2 HCV RNA decline allows, early during the course of treatment and with good accuracy, prediction of the final treatment outcome in almost half of patients with chronic hepatitis C in clinical practice. This finding, however, awaits independent external validation. Third, early virological events after the start of treatment are strictly related to a number of factors relevant to both the host and the virus. Interestingly, all of these factors have long been applied to the a priori prediction of treatment outcome [23] .
To account for the pretreatment HCV RNA level, we evaluated the relative reduction in HCV RNA level from baseline, calculating for each patient a log 10 HCV RNA value. This (t Ϫt ) 0 2 D procedure allows the comparison of patients, although the results are less reliable in cases of low baseline HCV RNA level because of the relatively low sensitivity of the assay used (615 IU/mL). Nonetheless, through this approach we were able to verify that patient groups with different final treatment outcomes may be differentiated as early as 2 days after the start of treatment.
We obtained clinically valuable data by measuring HCV RNA levels 2 days after the start of treatment. At this early stage, the extent of the viral load decline has positive and negative predictive values comparable to those of the RVR or EVR evaluations performed much later [30] [31] [32] [33] . To account for realworld clinical experience, in addition to an ITT analysis we also ran a per-protocol prediction analysis that excluded patients who showed excellent virological responses but discontinued treatment prematurely. This allowed us to improve the positive predictive value of the day 2 HCV RNA decline, which reached a 93% probability of a SVR for a decrease 12.5 logs.
Accumulating evidence suggests that insulin resistance is a key pathophysiologic feature of chronic hepatitis C, one that correlates with steatosis and fibrosis progression [25, 26] . Recent data suggest that the greater the pretreatment insulin resistance, the smaller the chance of a SVR [16, 17] , and that insulin resistance tends to wane after treatment-induced viral clearance [17, 27] . Our findings corroborate these data, showing for the first time that the deleterious effect of insulin resistance is manifest very early during the course of treatment. It appears that insulin resistance affects the direct antiviral effect of interferon, as emerging data from in vitro and in vivo studies are showing [28, 29] .
Our study has some limitations. It is a single-center analysis, performed on genetically homogeneous patients. Moreover, only HCV genotypes 1, 2, and 3 were represented. Finally, the quantitative assay used has a relatively low sensitivity (615 IU/ mL) compared with those of the latest real-time PCR-based tests, which were not available at the time we initiated the study.
In conclusion, the study of first-phase HCV RNA kinetics appears to provide important information on the intrinsic susceptibility of HCV to interferon. We believe that evaluation of the early HCV RNA kinetics during combination antiviral treatment should enter into clinical practice. Furthermore, our prediction model based on 2 cutoff values could have 2-fold relevance: it might allow immediate discontinuation of treatment when it appears to be ineffective, and it could boost patient adherence when a favorable outcome may be foreseen despite significant toxicity. Early withdrawal of ineffective medications could also dramatically reduce health and financial costs. We found for the first time that insulin resistance affects treatment response at a very early stage. Unraveling the molecular bases of this influence will likely provide novel tools for the management of chronic hepatitis C. 
